Literature DB >> 18023042

A phenotype for genetic studies of successful cognitive aging.

Jeremy M Silverman1, Michal Schnaider-Beeri, Hillel T Grossman, James Schmeidler, Joy Y Wang, Rachel C Lally.   

Abstract

Survival from Alzheimer's disease (AD) and other dementias into late old age may be a useful phenotype for genetic studies of successful cognitive aging. To support molecular genetics studies for successful cognitive aging, we conducted a two-stage study to determine an optimal age phenotype for successful cognitive aging. First, risk of AD was evaluated, through informant interviews, in 4,794 parents and siblings of 976 elderly nondemented probands who were divided into three different proband age groups: those aged 60-74, 75-89, and 90+. Relatives of probands aged 90+ had a significantly lower risk than the relatives of the other two proband groups. Second, this sample was combined with an earlier sample (combined nondemented elderly probands: n = 2,025; relatives: n = 10,506), and a series of proband age groups (i.e., 75-79, 80-84, 85-89, 90+) were used to determine which optimally identifies a group of relatives with low AD risk. Using the relatives of the nondemented proband aged 60-74 as the reference group, there were reductions in cumulative risk among relatives of probands aged 85-89 and 90+, but only the latter group also showed significant reductions to the relatives of probands aged 75-79, 80-84, and 85-89. This pattern of results varied little by sex. Finally, cumulative AD risk curves were similar between relatives of probands aged 90-94 and 95+. These results suggest that age 90 is an optimal age threshold to use for both men and women in genetic studies seeking to identify genes associated with successful cognitive aging. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2008        PMID: 18023042     DOI: 10.1002/ajmg.b.30483

Source DB:  PubMed          Journal:  Am J Med Genet B Neuropsychiatr Genet        ISSN: 1552-4841            Impact factor:   3.568


  7 in total

1.  The neuropsychological performance of nondemented Puerto Rican nonagenarians.

Authors:  José R Carrión-Baralt; Josefina Meléndez-Cabrero; Michal Schnaider Beeri; Mary Sano; Jeremy M Silverman
Journal:  Dement Geriatr Cogn Disord       Date:  2009-03-17       Impact factor: 2.959

2.  Haemoglobin A(1c) and cognitive function in very old, cognitively intact men.

Authors:  Jennifer Huang; James Schmeidler; Michal S Beeri; Clive Rosendorff; Simmi Bhatia; Rebecca K West; Irina N Bespalova; Rizalina Mavris; Jeremy M Silverman
Journal:  Age Ageing       Date:  2011-09-18       Impact factor: 10.668

3.  C-reactive protein and familial risk for dementia: a phenotype for successful cognitive aging.

Authors:  Jeremy M Silverman; James Schmeidler; Michal S Beeri; Clive Rosendorff; Mary Sano; Hillel T Grossman; José R Carrión-Baralt; Irina N Bespalova; Rebecca West; Vahram Haroutunian
Journal:  Neurology       Date:  2012-08-15       Impact factor: 9.910

4.  Heritability of cognitive functions in families of successful cognitive aging probands from the Central Valley of Costa Rica.

Authors:  Tiffany A Greenwood; Michal S Beeri; James Schmeidler; Daniel Valerio; Henriette Raventós; Lara Mora-Villalobos; Karla Camacho; José R Carrión-Baralt; Gary Angelo; Laura Almasy; Mary Sano; Jeremy M Silverman
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

5.  Does compensatory neural activity survive old-old age?

Authors:  Kirk R Daffner; Xue Sun; Elise C Tarbi; Dorene M Rentz; Phillip J Holcomb; Jenna L Riis
Journal:  Neuroimage       Date:  2010-08-07       Impact factor: 6.556

6.  Memory activation in healthy nonagenarians.

Authors:  Michal Schnaider Beeri; Hedok Lee; Hu Cheng; Daniel Wollman; Jeremy M Silverman; Isak Prohovnik
Journal:  Neurobiol Aging       Date:  2009-04-01       Impact factor: 4.673

7.  The mouse attentional-set-shifting task: a method for assaying successful cognitive aging?

Authors:  Jared W Young; Susan B Powell; Mark A Geyer; Dilip V Jeste; Victoria B Risbrough
Journal:  Cogn Affect Behav Neurosci       Date:  2010-05       Impact factor: 3.282

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.